2022-24 Mpox (Monkeypox) Outbreak:
Global Trends

World Health Organization

Produced on 17 September 2024

logo

Key figures

Totals for key countries

Democratic Republic of the Congo: totals for 2024

As of 15 September 2024

Cases*

25 757

Lab confirmed cases

5 399

Deaths*

806

Lab confirmed deaths

25

Burundi: totals for 2024

As of 15 September 2024

Cases*

1 557

Lab confirmed cases

564

Deaths*

0

Lab confirmed deaths

0

*Note that cases here refers to all cases, including suspected and laboratory confirmed cases. Laboratory confirmed cases are a subset of all cases. The same applies to deaths and laboratory confirmed deaths. In instances where suspected cases are tested and the laboratory results are negative, these cases are not retrospectively removed from the total case numbers. In the DRC, around 45% of cases were tested, and around 50% of tested cases were positive in 2024.

Totals for Africa

Data as updated weekly; from 01 January 2022 to 15 September 2024. Note that data shown here refers to laboratory confirmed cases only, and are collected from the continent of Africa, across the WHO African and Eastern Mediterranean regions.

Total lab confirmed cases in 2024

6 201

Total lab confirmed deaths in 2024

32

Countries reporting cases in 2024

15

Total lab confirmed cases

8 604

Total lab confirmed deaths

55

Countries reporting cases

20

Work is ongoing to incorporate suspected cases and deaths of mpox within countries in Africa.

Global totals

Data as updated monthly; from 01 January 2022 to 31 August 2024

Total lab confirmed cases in August 2024

2 082

Total lab confirmed deaths in August 2024

1

Countries reporting cases in August 2024

48

Total lab confirmed cases in 2024

11 095

Total lab confirmed deaths in 2024

50

Countries reporting cases in 2024

70

Total lab confirmed cases

106 310

Total lab confirmed deaths

234

Countries reporting cases

123

Clades detected globally

Data as reported from 01 January 2022 to 15 September 2024. Clade detection includes cases associated with local transmission and imported cases. Data is based on a combination of sequencing databanks, published literature, epidemiological links, and communication to WHO since 2022.

Map can be clicked to view on a larger scale

1 Overview

This report provides an overview of the mpox1 epidemiological situation in Africa, on a weekly basis (as of 15 September 2024), as well as the global epidemiological situation on a monthly basis (as of August 2024).

Data in this report are based on global data surveillance data collected from 01 January 2022, initiated due to the unprecedented human to human spread of monkeypox virus (MPXV) globally occurring in the same year.

On 14 August 2024, under the International Health Regulations (2005), the WHO Director General declared that the increase in mpox cases in the Democratic Republic of the Congo and its expansion to neighboring countries constitutes a Public Health Emergency of International Concern (PHEIC). This spread presents a public health risk to other Member States and requires a coordinated international response.

Based on currently available information, the spread of mpox cases in the Democratic Republic of the Congo is attributed to two main outbreaks - spread of MPXV clade Ia in Equateur and other previously affected provinces of the country, and the spread of clade Ib MPXV in the provinces of North and South Kivu, as well as several clade Ib cases detecrted in Kinshasa. Current sequencing in the country is limited and clade distribution might be broader than what is currently known.

WHO conducted the latest global mpox rapid risk assessment in August 2024. Based on the available information, the risk was assessed as:

  • In eastern Democratic Republic of the Congo and neighbouring countries: high.
  • In areas of the Democratic Republic of the Congo where mpox is endemic: high.
  • In Nigeria and other countries of West, Central and East Africa where mpox is endemic: moderate.
  • In all other countries in Africa and around the world: moderate.

Please note that regardless of geographic area, epidemiological context, biological sex, gender identity or sexual behaviour, individual-level risk is largely dependent on individual factors such as exposure risk and immune status.

This report mainly focuses on laboratory confirmed case and deaths2 as defined by WHO’s working case definition published in the Surveillance, case investigation and contact tracing for monkeypox interim guidance. In Africa, laboratory confirmed and suspected cases are both shown where possible. Note that countries3 may use their own case definitions separate from those outlined in the above document.

 


  1. On of 28 November 2022, WHO recommended using the name mpox as a new name for monkeypox. The words were used synonymously for one year as the term monkeypox was phased out. The virus causing mpox is named monkeypox virus (MPXV).

  2. For the WHO European region, both confirmed and probable cases are included within confirmed case counts and detailed case data.

  3. Throughout this document, any use of the word country should be considered shorthand for a country, area, or territory


2 Situation in Africa

This section of the report is jointly authored by the WHO Regional Office for Africa, the WHO Regional Office for the Eastern Mediterranean4 and WHO Headquarters.

Since 1 January 2022, cases of mpox have been reported to WHO from 20 Member States across Africa. As of 15 September 2024 , a total of 8 604 laboratory confirmed cases, including 55 deaths, have been reported to WHO.

In 2024, as of 15 September 2024, 15 countries have reported 6 201 confirmed cases, including 32 deaths. The three countries with the majority of the cases in 2024 are Democratic Republic of the Congo, (n = 5 399), Burundi, (n = 564), and Nigeria, (n = 55).

A significant number of suspected mpox cases, that are clinically compatible with mpox remain untested due to limited diagnostic capacity in some African countries and thus never get confirmed. For this reason, we include suspected cases in this section of the report.

In 2024, 14 countries have reported both 29 342 suspected and laboratory tested cases, including 812 suspected and confirmed deaths.

This indicator should be interpreted with caution, as suspected mpox cases are recorded according to varying national case definitions. In some countries, suspected cases that undergo testing are not removed from the count, regardless of whether the test result is positive (confirmed case) or negative (discarded case). Moreover, not all countries have robust surveillance systems for mpox, meaning reported case counts are likely underestimate the extent of community transmission.

Case definitions for some countries can be seen in the case definitions subsection.

 


  1. On the African continent there are 47 Member States in the WHO African Region and seven in the Eastern Mediterranean Region.

2.1 Outbreak status and MPXV clade distribution

The distribution of clades reported in Africa, and the outbreak status of the continent is shown in the maps below. Countries with active transmission are defined as those reporting cases in the past 28 days. The distribution of reported mpox clades in Africa is also shown below. It should be noted that in many cases, sequencing may not capture all circulating clades, leading to under-representation of where clades are circulating.

Maps can be clicked to view on a larger scale.

2.1.1 Outbreak status

2.1.2 Clade Ia, Ib, and II (a and/or b) presence

2.1.3 Confirmed cases in the past four weeks

Note that the 28-day period used here is relative to the date cases were last reported in each country. Where countries have not reported cases in the past 28 days, this is not calculated.

2.2 Epidemic curves

Epidemic curve shown by week for cases reported up to 15 Sep 2024. Note that for the purposes of these epidemic curves, countries with more than one clade present are presented in multiple epidemic curves. The most recent weeks presented in the epidemic curves should be interpreted with caution, as there are delays associated with reporting.

2.2.1 Confirmed cases in all countries in Africa

2.2.2 Confirmed cases in clade Ib countries

2.2.3 Confirmed cases in clade Ia countries

2.2.4 Clade II (a and/or b) countries

2.2.5 All cases in Africa

All cases, including suspected and lab confirmed cases are shown from 2024, only for countries where data are available. A subset of suspected cases are tested, of which some go on to become confirmed cases.


2.3 Maps

Maps can be clicked to view on a larger scale. Note that data are only shown for Africa - data from elsewhere are reflected in the global sections of the report.

2.3.1 Cumulative confirmed cases

2.3.2 Cumulative confirmed cases in 2024

2.3.3 Cumulative confirmed deaths

2.3.4 Cumulative confirmed deaths in 2024


2.4 Data by country

2.4.1 Laboratory confirmed cases

Summary of Laboratory confirmed mpox cases
As of 15 Sep 2024
Country Total cases Total deaths Case fatality ratio (%) Cases in 20241 Deaths in 20241 Cases in the past four weeks2 Deaths in the past four weeks2 Clades detected in country Date of last reported case
Democratic Republic of the Congo 6,644 27 0% 5,399 25 794 0 Clades Ia and Ib 15 September 2024
Burundi 564 0 0% 564 0 411 0 Clade Ib 15 September 2024
Nigeria 916 9 1% 55 0 17 0 Clade II (a and/or b) 1 September 2024
Central African Republic 97 2 2% 50 1 5 0 Clade Ia 15 September 2024
Côte d’Ivoire 45 1 2% 45 1 12 0 Clade II (a and/or b) 15 September 2024
South Africa 30 3 10% 25 3 1 0 Clade II (a and/or b) 8 September 2024
Congo 47 2 4% 21 0 2 0 Clade Ia 25 August 2024
Liberia 28 0 0% 11 0 5 0 No information 15 September 2024
Uganda 11 0 0% 11 0 8 0 Clade Ib 8 September 2024
Cameroon 51 5 10% 6 2 1 0 Clades Ia and II (a and/or b) 8 September 2024
Kenya 5 0 0% 5 0 4 0 Clade Ib 8 September 2024
Rwanda 4 0 0% 4 0 – – Clade Ib 4 August 2024
Gabon 2 0 0% 2 0 2 0 No information 1 September 2024
Morocco 6 0 0% 2 0 1 0 Clade II (a and/or b) 15 September 2024
Guinea 1 0 0% 1 0 1 0 No information 8 September 2024
Benin 3 0 0% 0 0 – – Clade II (a and/or b) 26 June 2022
Egypt 3 0 0% 0 0 – – Clade II (a and/or b) 18 December 2022
Ghana 127 4 3% 0 0 – – Clade II (a and/or b) 14 May 2023
Mozambique 1 0 0% 0 0 – – Clade II (a and/or b) 9 October 2022
Sudan 19 1 5% 0 0 – – Clade Ia 9 April 2023
Total 8,604 54 1% 6,201 32 1264 0 – –
1 The past four weeks are calculated from the date of last reported case in a country to account for reporting delays. In cases where the last reported case is more than four weeks ago, the value is not shown.
2 From 19 Aug 2024 to 15 Sep 2024

2.4.2 All cases

Summary of Suspected and Laboratory tested mpox cases
As of 15 Sep 2024
Country Cases in 20241,2 Confirmed cases in 20242 Deaths in 20241,2 Confirmed deaths in 20242 Cases in last four weeks1,3 Confirmed cases in last four weeks3 Dases in last four weeks1,3 Confirmed deaths in last four weeks3 Date of last case reported
Democratic Republic of the Congo 25,757 5,399 806 25 7,049 794 165 0 15 September 2024
Burundi 1,557 564 0 0 985 411 0 0 15 September 2024
Nigeria 935 55 0 0 203 17 0 0 1 September 2024
Central African Republic 285 50 1 1 20 5 0 0 15 September 2024
Congo 184 21 0 0 24 2 0 0 25 August 2024
Côte d’Ivoire 176 45 0 1 120 12 0 0 15 September 2024
Uganda 120 11 0 0 50 8 0 0 8 September 2024
Kenya 115 5 0 0 97 4 0 0 8 September 2024
Liberia 85 11 0 0 19 5 0 0 15 September 2024
Cameroon 54 6 2 2 18 1 0 0 8 September 2024
Guinea 30 1 0 0 30 1 0 0 8 September 2024
South Africa 25 25 3 3 1 1 0 0 8 September 2024
Gabon 15 2 0 0 15 2 0 0 1 September 2024
Rwanda 4 4 0 0 – – – – 4 August 2024
Total 29,342 6,199 812 32 8,631 1,263 165 0 –
1 Cases include both suspected cases and laboratory confirmed cases.
2 The past four weeks are calculated from the date of last reported case in a country to account for reporting delays. In cases where the last reported case is more than four weeks ago, the value is not shown.
3 From 19 Aug 2024 to 15 Sep 2024


2.5 Epidemic curves by country

Epidemic curve shown by week for cases reported up to 15 Sep 2024.

All cases, including suspected and laboratory tested cases are shown from 2024 where data are available. In some countries, suspected cases that undergo testing are not removed from the count, regardless of whether the test result is positive (confirmed case) or negative (discarded case).

2.5.1 Laboratory confirmed cases

Benin

Burundi

Cameroon

Central African Republic

Congo

Côte d’Ivoire

Democratic Republic of the Congo

Egypt

Gabon

Ghana

Guinea

Kenya

Liberia

Morocco

Mozambique

Nigeria

Rwanda

South Africa

Sudan

Uganda

2.5.2 All cases

Burundi

Cameroon

Central African Republic

Congo

Côte d’Ivoire

Democratic Republic of the Congo

Gabon

Guinea

Kenya

Liberia

Nigeria

Rwanda

South Africa

Uganda

2.6 Case definitions

This section includes the national case definition used in African countries in order to provide more context for the interpretation of data, especially of suspected cases.

Case definitions for suspected cases are shown for the following countries below:

2.6.1 Burundi

Suspected Case:

Any person presenting with sudden onset of fever >38.3°C (101°F), intense headaches, adenopathy, back pain, myalgia, and intense weakness, followed 1-3 days later by a vesiculopustular skin rash that develops progressively, often starting on the face (more dense) and then spreading to other parts of the body, including the soles of the feet and palms of the hands.

Confirmed Case:

Any case that has been clinically and epidemiologically diagnosed with mpox and laboratory confirmed.

2.6.2 Democratic Republic of the Congo

Suspected case:

A person with sudden onset of high fever followed by a vesiculopustular rash predominantly on the face and present on the palms of the hands and soles of the feet; OR presence of at least 5 smallpox-like scars,

OR

Any person with fever > 38.3 °C (101 F), severe headache, lymphadenopathy, back pain, myalgia, and severe weakness, followed 1-3 days later by a progressive rash that often begins on the face (more dense) and then spreads elsewhere on the body, including the soles of the feet and palms of the hands.

Confirmed case:

Any case for which the clinical and epidemiological diagnosis of mpox has been laboratory confirmed.


Data for download

Data by country can be downloaded as a csv file by clicking the button below. The data include the number of new cases and deaths reported each week, as well as the total number of cases and deaths reported to date. The data are current as of 15 Sep 2024.

 




3 Global situation update

All of the following data in this report are presented in the context of the ongoing global mpox outbreak. The data presented here are based on the most recent complete month of data reported to WHO as of 31 August 2024.

Since 1 January 2022, cases of mpox have been reported to WHO from 123 Member States across all 6 WHO regions. As of 31 August 2024 , a total of 106 310 laboratory confirmed cases and 0 probable cases, including 234 deaths, have been reported to WHO.

As of August 2024, the number of monthly reported new cases has increased by 15.6%, compared to the previous month. The majority of cases reported in the past month were notified from the African Region (62.3%) and the European Region (13.7%).

The 10 most affected countries globally since 1 January 2022 are: United States of America (n = 33 812), Brazil (n = 12 206), Spain (n = 8 240), Democratic Republic of the Congo (n = 6 092), France (n = 4 307), Colombia (n = 4 262), Mexico (n = 4 155), The United Kingdom (n = 4 058), Peru (n = 3 939), and Germany (n = 3 909). Together, these countries account for 79.9% of the cases reported globally.

In the most recent month of reporting, 48 countries have reported cases, 33, of which reported an increase in monthly case counts.

In the past month, 1 country reported their first case. Countries which reported their first case in the past month are: Gabon.

Global aggregated data are collected through direct reporting from Member States to WHO and its partners or from official country sources. The below epidemic curve shows the aggregated number of cases by month according to the date of case reporting.

3.1 Epidemic curves

3.1.1 Global (cases)

Epidemic curve shown by month for cases reported up to 31 Aug 2024 to avoid showing incomplete months of data.

3.1.2 Global (deaths)

Epidemic curve shown by month for deaths reported up to 31 Aug 2024 to avoid showing incomplete months of data.

3.1.3 By WHO Region (cases)

Epidemic curve shown by month for cases reported up to 31 Aug 2024 to avoid showing incomplete months of data. Note different y-axis scales.

3.1.4 By WHO Region (deaths)

Epidemic curve shown by month for deaths reported up to 31 Aug 2024 to avoid showing incomplete months of data. Note different y-axis scales.

3.1.5 Top 10 countries (cases)

Epidemic curve shown by month for cases reported up to 31 Aug 2024 to avoid showing incomplete months of data. Note different y-axis scales.

3.1.6 By country

Andorra

Argentina

Aruba

Australia

Austria

Bahamas

Bahrain

Barbados

Belgium

Benin

Bermuda

Bolivia (Plurinational State of)

Bosnia and Herzegovina

Brazil

Bulgaria

Burundi

Cambodia

Cameroon

Canada

Central African Republic

Chile

China

Colombia

Congo

Costa Rica

Croatia

Cuba

Curaçao

Cyprus

Czechia

Côte d’Ivoire

Democratic Republic of the Congo

Denmark

Dominican Republic

Ecuador

Egypt

El Salvador

Estonia

Finland

France

Gabon

Georgia

Germany

Ghana

Gibraltar

Greece

Greenland

Guadeloupe

Guam

Guatemala

Guinea

Guyana

Honduras

Hungary

Iceland

India

Indonesia

Iran (Islamic Republic of)

Ireland

Israel

Italy

Jamaica

Japan

Jordan

Kenya

Lao People’s Democratic Republic

Latvia

Lebanon

Liberia

Lithuania

Luxembourg

Malaysia

Malta

Martinique

Mexico

Monaco

Montenegro

Morocco

Mozambique

Nepal

Netherlands

New Caledonia

New Zealand

Nigeria

Norway

Oman

Pakistan

Panama

Paraguay

Peru

Philippines

Poland

Portugal

Qatar

Republic of Korea

Republic of Moldova

Romania

Russian Federation

Rwanda

Saint Martin

San Marino

Saudi Arabia

Serbia

Singapore

Slovakia

Slovenia

South Africa

Spain

Sri Lanka

Sudan

Sweden

Switzerland

Thailand

The United Kingdom

Trinidad and Tobago

Türkiye

Uganda

Ukraine

United Arab Emirates

United States of America

Uruguay

Venezuela (Bolivarian Republic of)

Viet Nam

3.3 Maps

Note: Maps can be clicked to view on a larger scale

3.3.1 Cumulative cases

3.3.2 Cumulative deaths

3.3.3 Cases in the past month

3.3.4 Monthly change in cases

3.4 Tables

3.4.1 Cumulative cases and deaths by WHO Region

Total mpox cases, by WHO region
Data as of August 2024
WHO Region Total cases1 Total deaths1 Cases in Jul 2024 Cases in Aug 2024 Monthly % change in cases Month most recent cases reported
Region of the Americas 64,879 148 447 207 −54.0% Aug 2024
European Region 27,965 9 151 285 89.0% Aug 2024
African Region 7,662 54 1,016 1,298 28.0% Aug 2024
Western Pacific Region 3,979 10 163 274 68.0% Aug 2024
South-East Asia Region 956 11 15 16 6.7% Aug 2024
Eastern Mediterranean Region 869 2 9 2 −78.0% Aug 2024
1 From Jan 2022


3.4.2 Cumulative cases and deaths by country

Total Mpox cases, by WHO region
From 1 Jan 2022. Data as of 31 Aug 2024
Total Confirmed Cases Total Probable Cases Total Deaths
Region of the Americas
United States of America 33,812 0 61
Brazil 12,206 0 16
Colombia 4,262 0 0
Mexico 4,155 0 35
Peru 3,939 0 23
Canada1 1,649 0 0
Chile 1,461 0 3
Argentina 1,181 0 2
Ecuador 605 0 3
Guatemala 406 0 1
Bolivia (Plurinational State of) 266 0 0
Panama 241 0 1
Costa Rica 225 0 1
Paraguay 126 0 0
Dominican Republic 110 0 1
El Salvador 104 0 0
Honduras 44 0 0
Jamaica 21 0 0
Uruguay 19 0 0
Venezuela (Bolivarian Republic of) 12 0 0
Cuba 8 0 1
Martinique 7 0 0
Bahamas 4 0 0
Trinidad and Tobago 4 0 0
Aruba 3 0 0
Curaçao 3 0 0
Guyana 2 0 0
Barbados 1 0 0
Bermuda 1 0 0
Guadeloupe 1 0 0
Saint Martin 1 0 0
European Region
Spain 8,240 0 3
France 4,307 0 0
The United Kingdom 4,058 0 0
Germany 3,909 0 0
Netherlands 1,327 0 0
Portugal 1,206 0 2
Italy 1,057 0 0
Belgium 814 0 2
Switzerland 588 0 0
Austria 350 0 1
Israel 321 0 0
Sweden 302 0 0
Ireland 250 0 0
Poland 225 0 0
Denmark 204 0 0
Norway 109 0 0
Greece 99 0 0
Czechia 85 0 1
Hungary 85 0 0
Luxembourg 61 0 0
Romania 48 0 0
Slovenia 47 0 0
Finland 43 0 0
Serbia 40 0 0
Malta 37 0 0
Croatia 34 0 0
Iceland 17 0 0
Slovakia 16 0 0
Türkiye 12 0 0
Estonia 11 0 0
Bosnia and Herzegovina 9 0 0
Bulgaria 7 0 0
Gibraltar 6 0 0
Latvia 6 0 0
Cyprus 5 0 0
Lithuania 5 0 0
Ukraine 5 0 0
Andorra 4 0 0
Russian Federation 4 0 0
Monaco 3 0 0
Georgia 2 0 0
Greenland 2 0 0
Montenegro 2 0 0
Republic of Moldova 2 0 0
San Marino 1 0 0
African Region
Democratic Republic of the Congo 6,092 0 27
Nigeria 911 0 9
Burundi 231 0 0
Ghana 127 0 4
Central African Republic 94 0 2
Cameroon 50 0 5
Congo 47 0 2
Côte d’Ivoire 41 0 1
South Africa 29 0 3
Liberia 23 0 0
Uganda 6 0 0
Rwanda 4 0 0
Benin 3 0 0
Kenya 2 0 0
Gabon 1 0 0
Mozambique 1 0 1
Guinea 0 0 0
Western Pacific Region
China2 2,582 0 1
Australia 624 0 0
Japan 248 0 1
Viet Nam 203 0 8
Republic of Korea 166 0 0
Singapore 64 0 0
New Zealand 53 0 0
Philippines 14 0 0
Cambodia 13 0 0
Malaysia 9 0 0
Guam 1 0 0
New Caledonia 1 0 0
Lao People's Democratic Republic 1 0 0
South-East Asia Region
Thailand 833 0 10
Indonesia 88 0 0
India 30 0 1
Sri Lanka 4 0 0
Nepal 1 0 0
Eastern Mediterranean Region
Saudi Arabia 764 0 0
United Arab Emirates 28 0 0
Lebanon 27 0 0
Sudan 19 0 1
Pakistan 11 0 1
Qatar 5 0 0
Morocco 5 0 0
Egypt 3 0 0
Oman 3 0 0
Bahrain 2 0 0
Iran (Islamic Republic of) 1 0 0
Jordan 1 0 0
-
Total 106,310 0 234
1 Date information is unavailable for 45 cases in Canada
2 Cases shown include those in mainland China (2109), Hong Kong SAR (67), Taipei (404), and Macao (2)


3.4.9 Countries reporting cases in the previous month

Countries reporting cases in August
Country New cases New deaths
African Region
Democratic Republic of the Congo 1,013 0
Burundi 222 0
Côte d’Ivoire 32 1
Nigeria 12 0
Central African Republic 6 0
Uganda 4 0
Congo 2 0
Rwanda 2 0
South Africa 2 0
Gabon 1 0
Kenya 1 0
Liberia 1 0
Western Pacific Region
Australia 245 0
China 15 0
Philippines 5 0
Republic of Korea 5 0
Singapore 3 0
Japan 1 0
European Region
Spain 136 0
The United Kingdom 40 0
France 24 0
Germany 23 0
Netherlands 19 0
Portugal 10 0
Switzerland 9 0
Israel 4 0
Belgium 3 0
Czechia 3 0
Austria 2 0
Malta 2 0
Norway 2 0
Poland 2 0
Sweden 2 0
Denmark 1 0
Ireland 1 0
Italy 1 0
Romania 1 0
Region of the Americas
United States of America 113 0
Brazil 33 0
Argentina 26 0
Mexico 23 0
Canada 8 0
Colombia 2 0
Ecuador 2 0
South-East Asia Region
Thailand 13 0
India 3 0
Eastern Mediterranean Region
Pakistan 1 0
Saudi Arabia 1 0





4 Detailed case data

Detailed case data are acquired via direct reporting of case-based data from Member States to WHO. Data from cases are reported1 according to the WHO minimum dataset under the International Health Regulations (IHR 2005) Article 6. Completeness of records is variable, meaning denominators for variables may be different from one another. All of the following is derived from detailed case data, and as a result, overall numbers may not be reflective of figures shown with aggregate case numbers. All detailed cases shown are confirmed cases, where the reporting date occurred after 01 January 2022.


  1. Note that a small number of detailed case reports are constructed from official public reports about individual cases.

4.1 Reporting coverage

The detailed case dataset was last updated on August 2024. As of this date, the total number of detailed confirmed cases reported is 95 495, representing 89.8% of all aggregated cases reported.

The table below indicates the reporting coverage between reported aggregated confirmed cases and detailed confirmed cases by countries and per region.

4.1.1 Table - Coverage by region

Mpox reporting completeness
As of 31 Aug 2024
Total Confirmed Cases Total Detailed Confirmed Cases1 % Detailed Cases reported
Region of the Americas 64,879 63,941 98.6%
European Region 27,965 27,774 99.3%
African Region 7,662 672 8.8%
Western Pacific Region 3,979 2,902 72.9%
South-East Asia Region 956 118 12.3%
Eastern Mediterranean Region 869 88 10.1%
1 Note that in rare cases total detailed cases may exceed total confirmed cases due to ongoing data cleaning issues



4.3 Case profile (overall)

As of 31 Aug 2024, the vast majority of cases for which detailed case based data are available are not associated with the outbreak of clade Ib, or the African region. For this reason the following analysis is overwhelmingly reflective of the global situation outside of Africa and clade Ib.

Key features of these cases are as follows:

  • 96.4% (87 794/91 119) of cases with available data are male, the median age is 34 years (IQR: 29 - 41).

  • Males between 18-44 years old continue to be disproportionately affected by this outbreak as they account for 79.2% of reported cases.

  • Of all cases with available data, 3.6% (3 325/91 119) are female:

    • The majority of these cases are reported from the Region of the Americas (2 518/3 325; 76%) and the European Region (456/3 325; 14%)

    • The most commonly reported form of transmission is via sexual encounters (259/503; 51%)

  • Of the 95 068 cases where age was available, there were 1 210 (1.3%) cases reported aged 0-17, out of which 346 (0.4%) were aged 0-4:

    • The majority of cases aged 0-17 are reported from the Region of the Americas (763 /1 210; 63%).
  • 59 cases were reported to be pregnant or recently pregnant. Of these:

    • 3, 12, and 9 cases were in their first, second, and third trimesters respectively. 32 were in an unknown trimester, and 0 were six weeks or less post-partum.

    • The median age was 27 years old (IQR: 22 - 31).

    • 13 of these cases were known to be hospitalized. 0 were known to be admitted to ICU and 0 were known to have died.

    • The most common mode of transmission was sexual encounter (4/7 cases where route was known).

  • Among cases with known data on sexual behaviour, 85.0% (23 800/27 988) identified as men who have sex with men.

  • Among those with known HIV status, 51.8% (18 451/35 599) were people living with HIV. Note that information on HIV status is not available for the majority of cases.

  • 1 367 cases were reported to be health workers. However, most were exposed in the community and further investigation is ongoing to determine which were due to occupational exposure.

  • Of all reported types of transmission, a sexual encounter was reported most commonly, with 19 022 of 22 588 (84.2%) of all reported transmission events.

  • Of all settings in which cases were likely exposed, the most common was in party setting with sexual contacts, with 4 386 of 6 349 (69.1%) of all reported exposure events.

As of 6 October 2023, the updated case reporting form no longer requires collection of exposure setting as an aspect of the case-based data. While we longer receive this information, we continue to present these data for the historical record.



4.3.1 Demographic Information

Note that the proportions shown below should be interpreted with caution. In some cases, a variable may be more likely to be filled in if the answer is yes than if the answer is no. This is most likely to be true for variables such as HIV status, health worker status, travel history, hospitalization, ICU, and death.

Case profiles
As of 31 Aug 2024
Reported values Unknown or Missing Value
Yes No
Men who have sex with men 23,800 (85.0%) 4,188 (15.0%) 67,498
Persons living with HIV 18,451 (51.8%) 17,148 (48.2%) 59,887
Health worker 1,367 (4.0%) 32,406 (96.0%) 61,713
Travel History 4,102 (15.7%) 21,992 (84.3%) 69,392
Sexual Transmission 19,021 (84.2%) 3,566 (15.8%) 72,899
Hospitalized1 6,258 (11.0%) 50,770 (89.0%) 38,458
ICU 49 (0.3%) 15,425 (99.7%) 80,012
Died 151 (0.3%) 58,562 (99.7%) 36,773
1 May be hospitalized for isolation or medical treatment



4.3.2 Age-sex pyramid



4.3.3 Age-sex pyramid by region

Note different x-axis scales.



4.3.4 Age-sex pyramid (Hospitalized cases)

Note that some cases represented below may be hospitalized for isolation rather than treatment purposes.



4.3.5 Age-sex pyramid (ICU cases)



4.3.6 Sexual behaviour by region



4.3.7 Transmission type

Transmission data were available for 22 588/95 495 (23.7%) of cases.

Transmission can occur during sex via skin-to-skin contact as well as via bodily fluids. While skin-to-skin contact with lesions remains an important transmission route, monkeypox virus has been isolated from semen samples and rectal swabs from confirmed cases. Note that person to person contact excludes known sexual, healthcare-associated, and mother to child transmission.



4.3.8 Exposure settings

Exposure setting data were available for 7 611/95 495 (8.0%) of cases.

Note that multiple exposure settings can be attributed to a single case. Here, differentiation between party settings and large events is determined by size of the event, although there is no formal size threshold to distinguish the two.



4.3.9 Transmission by exposure type

4.4 Case profile (excluding men who have sex with men)

As of this date in time, with regards to the outbreak of clade IIb, the multi-country mpox outbreak has been overwhelmingly concentrated in sexual networks of men who have sex with men. For this reason, understanding events in which individuals having other sexual behaviours have acquired mpox is important to monitor potential of sustained spillover into the general population. Note that the demographics of cases affected with clade Ib are not represented here.

The following outputs apply to cases with sexual behaviour reported as other than men who have sex with men. As above, note that reported sexual behaviour does not necessarily reflect persons who the case has had recent sexual history with nor does it imply sexual activity.

  • 76.9% (3 114/4 049) of cases with available data are male; the median age is 32 years (IQR: 26-41).

  • Males between 18-44 years old account for 61.8% of cases.

  • Among those with known HIV status 23.9% (757/3 168) were people living with HIV. Note that information on HIV status is not available for the majority of cases.

  • 98 cases were reported to be health workers. However, most were exposed in the community.

  • Of all reported types of transmission, sexual encounter was reported most commonly, with 474 of 905 (52.4%) of all reported transmission events.

  • Of all settings in which cases were likely exposed, the most common was in households, with 58 of 179 (32.4%) of all likely exposure categories.

4.4.1 Demographic Information

Note that the proportions shown below should be interpreted with caution. In some cases, a variable may be more likely to be filled in if the answer is yes than if the answer is no. This is most likely to be true for variables such as HIV status, health worker status, travel history, hospitalization, ICU, and death.

Case profiles (excluding men who have sex with men)
As of 31 Aug 2024
Reported values Unknown or Missing Value
Yes No
Men who have sex with men 0 4,188 (100.0%) 0
Persons living with HIV 757 (23.9%) 2,411 (76.1%) 1,020
Health worker 98 (6.3%) 1,450 (93.7%) 2,640
Travel History 244 (13.4%) 1,578 (86.6%) 2,366
Sexual Transmission 474 (52.4%) 431 (47.6%) 3,283
Hospitalized1 276 (12.6%) 1,919 (87.4%) 1,993
ICU 13 (1.2%) 1,114 (98.8%) 3,061
Died 10 (0.4%) 2,566 (99.6%) 1,612
1 May be hospitalized for isolation or medical treatment



4.4.2 Age-sex pyramid excluding men who have sex with men



4.4.3 Transmission type

Transmission data were available for 905/4 188 (21.6%) of cases.

Transmission can occur during sex via skin-to-skin contact as well as via bodily fluids. While skin-to-skin contact with lesions remains an important transmission route, monkeypox virus has been isolated from semen samples and rectal swabs from confirmed cases. Note that person to person contact excludes known sexual, healthcare-associated, and mother to child transmission.

All Genders



Male



Female



4.4.4 Exposure settings

Exposure setting data were available for 180/4 188 (4.3%) of cases that were not men who have sex with men.

Note that multiple exposure settings can be attributed to a single case. Here, differentiation between party settings and large events is determined by size of the event, although there is no formal size threshold to distinguish the two.

All Sexes



Male



Female



4.5 Case profile (recent cases)

This section of the report pertains specifically to the most recent six months of the outbreak, and case report forms that were reported in that time period (01 Mar 2024 - 31 Aug 2024).

In the last six months:

  • Of all cases with available information, 97% (2 334 / 2 397) of cases were male, and 87% (251 / 290) reported being as men who have sex with men.

  • Of all reported types of transmission, a sexual encounter was reported most commonly, with 385 of 411 (93.7%) of all reported transmission events.

4.5.1 Demographic information

Note that the proportions shown below should be interpreted with caution. In some cases, a variable may be more likely to be filled in if the answer is yes than if the answer is no. This is most likely to be true for variables such as HIV status, health worker status, travel history, hospitalization, ICU, and death.

Case profiles
From 01 Mar to 17 Sep 2024
Reported values Unknown or Missing Value
Yes No
Men who have sex with men 251 (86.6%) 39 (13.4%) 2,212
Persons living with HIV 244 (46.3%) 283 (53.7%) 1,975
Health worker 21 (2.5%) 831 (97.5%) 1,650
Travel History 104 (17.3%) 497 (82.7%) 1,901
Sexual Transmission 385 (93.7%) 26 (6.3%) 2,091
Hospitalized1 167 (10.3%) 1,449 (89.7%) 886
ICU 0 288 (100.0%) 2,214
Died 1 (0.1%) 1,323 (99.9%) 1,178
1 May be hospitalized for isolation or medical treatment



4.5.2 Age-sex pyramid, recent cases



4.5.3 Transmission type

Transmission data were available for 411/2 502 (16.4%) of cases.

Transmission can occur during sex via skin-to-skin contact as well as via bodily fluids. While skin-to-skin contact with lesions remains an important transmission route, monkeypox virus has been isolated from semen samples and rectal swabs from confirmed cases. Note that person to person contact excludes known sexual, healthcare-associated, and mother to child transmission.



4.6 Symptomatology

Although most cases in current outbreaks have presented with mild disease symptoms, monkeypox virus (MPXV) may cause severe disease in certain population groups (young children, pregnant women, immunosuppressed persons).

Among the cases who reported at least one symptom, the most common symptom is any rash and is reported in 88% of cases with at least one reported symptom. Note that identifying true denominators for symptomatology is difficult due to a general lack of negative reporting and symptom definitions that may vary between countries’ reporting systems.

A bar chart and table showing symptoms is shown below. Here any rash refers to one or more rash symptoms (systemic, oral, genital, or unknown location), and any lymphadenopathy refers to either general or local lymphadenopathy. Systemic rash included rash on the body, excluding mucosal and genital rash. Symptom information is shown for all cases where information was available reported from January 2022.

4.6.1 Bar chart - Symptoms

All cases

Male cases

Female cases

4.6.2 Table - Symptoms

Summary of symptoms
As of 31 Aug 2024
All Male Female
Any rash 31,959 (88.1%) 29,637 (88.7%) 1,096 (81.6%)
Fever 20,345 (56.1%) 19,466 (58.2%) 707 (52.7%)
Systemic rash 18,379 (50.7%) 17,444 (52.2%) 901 (67.1%)
Genital rash 18,130 (50.0%) 16,622 (49.7%) 374 (27.8%)
Any lymphadenopathy 10,120 (27.9%) 9,840 (29.4%) 219 (16.3%)
Headache 9,764 (26.9%) 9,215 (27.6%) 498 (37.1%)
Muscle ache 9,438 (26.0%) 8,281 (24.8%) 379 (28.3%)
General lymphadenopathy 8,201 (22.6%) 7,998 (23.9%) 143 (10.6%)
Fatigue 6,325 (17.4%) 6,169 (18.5%) 150 (11.2%)
Sore throat 5,333 (14.7%) 5,058 (15.1%) 224 (16.7%)
Local lymphadenopathy 5,217 (14.4%) 5,090 (15.2%) 125 (9.4%)
Rash, unknown location 3,512 (9.7%) 3,487 (10.4%) 23 (1.7%)
Oral rash 2,912 (8.0%) 2,600 (7.8%) 81 (6.0%)
Chills 2,279 (6.3%) 2,133 (6.4%) 113 (8.4%)
Cough 800 (2.2%) 731 (2.2%) 53 (4.0%)
Vomiting 776 (2.1%) 682 (2.0%) 50 (3.7%)
Lymphadenopathy, location unknown 471 (1.3%) 457 (1.4%) 14 (1.0%)
Anogenital pain and/or bleeding 387 (1.1%) 381 (1.1%) 6 (0.4%)
Asymptomatic 286 (0.8%) 261 (0.8%) 17 (1.3%)
Other 254 (0.7%) 249 (0.7%) 5 (0.4%)
Conjunctivitis 204 (0.6%) 165 (0.5%) 14 (1.0%)
Diarrhea 118 (0.3%) 96 (0.3%) 2 (0.1%)
Genital oedema 45 (0.1%) 44 (0.1%) 0

 


5 Genomic epidemiology

MPXV genetic sequences are routinely shared within NCBI GenBank and GISAID databases. Based on mutations and phylogenetic clustering, MPXV is currently divided into two major clades, clade I (one, formally Congo Basin clade) and clade II (two, formally West Africa clade). Each of these clades is further subdivided into two subclades: clade Ia and clade Ib within clade I; clade IIa and clade IIb within clade II.

Clade Ia circulates within multiple countries in Central Africa and is associated with regular spillover from an animal reservoir(s) with some onward person-to-person transmission. Clade Ia has been sampled in Cameroon, Central African Republic, Congo, Democratic Republic of the Congo, South Sudan and Sudan. Mixing of virus sequences from these countries within the clade Ia phylogenetic tree shows international movement of clade Ia viruses.

Clade Ib has recently emerged in eastern regions of the Democratic Republic of the Congo and is undergoing sustained person-to-person transmission. Recent cases of clade Ib have also been detected in Burundi, Kenya, Rwanda, Sweden, Thailand and Uganda. There is limited mutational diversity among clade Ib sequences. However, recent sequences from Kenya, Uganda, Sweden and Thailand share several mutations.

Clade IIa has rarely been isolated in humans with most available genetic sequences coming from animal species. Clade IIb has undergone sustained circulation within humans since at least 2016 and has caused a large ongoing outbreak from 2022 to present. The 2022-24 clade IIb outbreak is currently divided into 33 lineages which enable fine scale tracking.

The following phylogenetic visualisations were generated in R using the ggtree package.

5.1 Phylogeny of all MPXV clades

all_clades

5.2 Phylogeny of clade 1b

clade_Ib

5.3 Phylogeny of clade 1a

clade_Ia

 


6 Literature summary & epidemic parameters

In order to promote a better understanding of the dynamics of the mpox outbreak and to support forecasting work, in 2022, WHO undertook an effort to extract epidemiological parameters (incubation period, serival interval and generation interval) from the literature. The initial literature screening was performed and maintained by the Public Health Agency of Canada (PHAC). The overall search strategy was as follows:

  • Inclusion criteria: monkeypox and monkeypox virus
  • Study design:
    • Any study design including primary and secondary studies (both animal and human)
    • Guidelines and commentaries are not excluded but are not searched systematically.
  • Publication language: no restriction for peer-reviewed articles, grey literature is focused on English
  • Publication date: from April 14, 2022 – January 19, 2023
  • Bibliographic databases and other sources searched:
    • PubMed Scopus
    • Pre-print servers: Europe PMC, arXiv and SSRN
    • WHO, PHAC, CDC, ECDC, UKHSA

The tables below provide an overview of the most relevant estimates for incubation period and generation interval extracted from the literature where the following criteria are met:

  • Studies with a sample size greater than 5
  • Clear estimate of the specific parameter

The epidemic parameter tables are no longer updated, as the literature screening is no longer carried out.

6.1 Parameters

Incubation Period
As of 19 Jan 2023
Reference N Mean1 95% CrI (mean)1 95% CI (mean)1 SD1 Median1 95% CrI (median)1 IQR1 Range1 Distribution
Miura et al. [1] 18 8.5 6.6 - 10.9 - - - - - - Log-normal
Charniga et al. [2] 40 7.6 6.2 - 9.7 - 1.8 6.4 5.1 - 7.9 - - Log-normal
Rodríguez et al. [3] 45 - - - - - - - - -
Thornhill et al. [4] 23 - - - - 7.0 - - 3 - 20 -
Català et al. [5] 77 - - - - 6.0 - - 4 - 9 -
Tarín-Vicente et al. [6] 144 - - - - 7.0 - 5 - 10 1 - 19 -
Guzzetta et al. [7] 30 9.1 - 6.5 - 10.9 - - - - - Gamma
Mailhe et al. [8] 112 - - - - 6.0 - 3 - 8 - -
Moschese et al. [9] 16 - - - - 11.0 - 11 - 16 - -
Gomez-Garberi et al. [10] 14 - - - - 13.0 - - 3 - 30 -
O'Laughlin et al. [11] 527 7.0 - - - - - 4 - 9 - -
Angelo et al. [12] 78 - - - - 8.0 - 5 - 11 2 - 40 -
Madewell et al. [14] 35 5.6 4.3 - 7.8 - - - - - - -
Ward et al. [15] 54 7.8 6.6 - 9.2 - - - - - - Weibull
Besombes et al. [16] 29 - - - - 7.0 - 1 - 13 0 - 17 -
Kröger et al. [17] 209 8.2 - - 4.7 - - - - Log-normal
Source: PHAC
1 Units are in days




Serial Interval
As of 19 Jan 2023
Reference N Mean1 95% CrI (mean)1 SD1 Median1 95% CrI (median)1 Distribution
Guo et al. [13] 21 5.6 1.7 - 10.4 1.5 5.5 1.4 - 10.4 -
Madewell et al. [14] 57 8.5 7.3 - 9.9 - - - Gamma
Ward et al. [15] 79 9.5 7.4 - 12.3 - - - Gamma
Miura et al. [18] 34 9.4 - 6.2 - - Normal
Source: PHAC
1 Units are in days




Generation Interval
As of 19 Jan 2023
Reference N Mean1 95% CrI1 Distribution
Guzzetta et al. [7] 16 12.5 7.5 - 17.3 Gamma
Source: PHAC
1 Units are in days


6.2 Bibliography

  1. The incubation period for monkeypox cases confirmed in the Netherlands, May 2022 ( 658) medRxiv . Miura, Fuminari, van Ewijk, Catharina Else, Backer, Jantien A., Xiridou, Maria, Franz, Eelco, de Coul, Eline Op, Brandwagt, Diederik, van Cleef, Brigitte, van Rijckevorsel, Gini, Swaan, Corien, van den Hof, Susan, Wallinga, Jacco. #volume# (2022): 2022.06.09.22276068–> 10.1101/2022.06.09.22276068 ; http://medrxiv.org/content/early/2022/06/13/2022.06.09.22276068.abstract

  2. Estimating the incubation period of monkeypox virus during the 2022 multi-national outbreak ( 722) medRxiv . Charniga, Kelly, Masters, Nina B., Slayton, Rachel B., Gosdin, Lucas, Minhaj, Faisal S., Philpott, David, Smith, Dallas, Gearhart, Shannon, Alvarado-Ramy, Francisco, Brown, Clive, Waltenburg, Michelle A., Hughes, Christine M., Nakazawa, Yoshinori. #volume# (2022): 2022.06.22.22276713–> 10.1101/2022.06.22.22276713 ; http://medrxiv.org/content/early/2022/06/23/2022.06.22.22276713.abstract

  3. Epidemiologic Features and Control Measures during Monkeypox Outbreak, Spain, June 2022 ( 888) Emerg Infect Dis . Rodríguez, B. S., Herrador, B. R. G., Franco, A. D., Fariñas, M. P. S., Del Amo Valero, J., Llorente, A. H. A., de Agreda, Jpap, Malonda, R. C., Castrillejo, D., Chirlaque López, M. D., Chong, E. J., Balbuena, S. F., García, V. G., García-Cenoz, M., Hernández, L. G., Montalbán, E. G., Carril, F. G., Cortijo, T. G., Bueno, S. J., Sánchez, A. L., Linares Dópido, J. A., Lorusso, N., Martins, M. M., Martínez Ochoa, E. M., Mateo, A. M., Peña, J. M., Antón, A. I. N., Otero Barrós, M. T., Martinez, Mdcp, Jiménez, P. P., Martín, O. P., Rivas Pérez, A. I., García, M. S., Soria, F. S., Sierra Moros, M. J.. 28,2022/07/13 (2022): #pages#–> 10.3201/eid2809.221051 ; https://wwwnc.cdc.gov/eid/article/28/9/22-1051_article

  4. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 ( 933) N Engl J Med . Thornhill, J. P., Barkati, S., Walmsley, S., Rockstroh, J., Antinori, A., Harrison, L. B., Palich, R., Nori, A., Reeves, I., Habibi, M. S., Apea, V., Boesecke, C., Vandekerckhove, L., Yakubovsky, M., Sendagorta, E., Blanco, J. L., Florence, E., Moschese, D., Maltez, F. M., Goorhuis, A., Pourcher, V., Migaud, P., Noe, S., Pintado, C., Maggi, F., Hansen, A. E., Hoffmann, C., Lezama, J. I., Mussini, C., Cattelan, A., Makofane, K., Tan, D., Nozza, S., Nemeth, J., Klein, M. B., Orkin, C. M.. 2022/07/23 (2022): #pages#–> 10.1056/NEJMoa2207323 ; #URL#

  5. Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases ( 1008) Br J Dermatol . Català, A., Clavo Escribano, P., Riera, J., Martín-Ezquerra, G., Fernandez-Gonzalez, P., Revelles Peñas, L., Simón Gozalbo, A., Rodríguez-Cuadrado, F. J., Guilera Castells, V., De la Torre Gomar, F. J., Comunión Artieda, A., Fuertes de Vega, L., Blanco, J. L., Puig, S., García Miñarro Á, M., Fiz Benito, E., Muñoz-Santos, C., Repiso-Jiménez, J. B., Ceballos-Rodriguez, C., García Rodríguez, V., Castaño Fernández, J. L., Sánchez-Gutiérrez, I., Calvo López, R., Berna-Rico, E., de Nicolás-Ruanes, B., Corella Vicente, F., Tarín Vicente, E. J., Fernández de la Fuente, L., Riera-Martí, N., Descalzo-Gallego, M., Grau-Perez, M., García-Doval, I., Fuertes, I.. 2022/08/03 (2022): #pages#–> 10.1111/bjd.21790 ; #URL#

  6. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study ( 1074) Lancet . Tarín-Vicente, E. J., Alemany, A., Agud-Dios, M., Ubals, M., Suñer, C., Antón, A., Arando, M., Arroyo-Andrés, J., Calderón-Lozano, L., Casañ, C., Cabrera, J. M., Coll, P., Descalzo, V., Folgueira, M. D., García-Pérez, J. N., Gil-Cruz, E., González-Rodríguez, B., Gutiérrez-Collar, C., Hernández-Rodríguez, Á., López-Roa, P., de Los Ángeles Meléndez, M., Montero-Menárguez, J., Muñoz-Gallego, I., Palencia-Pérez, S. I., Paredes, R., Pérez-Rivilla, A., Piñana, M., Prat, N., Ramirez, A., Rivero, Á., Rubio-Muñiz, C. A., Vall, M., Acosta-Velásquez, K. S., Wang, A., Galván-Casas, C., Marks, M., Ortiz-Romero, P., Mitjà, O.. 2022/08/12 (2022): #pages#–> 10.1016/s0140-6736(22)01436-2 ; #URL#

  7. Early Estimates of Monkeypox Incubation Period, Generation Time, and Reproduction Number, Italy, May-June 2022 ( 1189) Emerg Infect Dis . Guzzetta, G., Mammone, A., Ferraro, F., Caraglia, A., Rapiti, A., Marziano, V., Poletti, P., Cereda, D., Vairo, F., Mattei, G., Maraglino, F., Rezza, G., Merler, S.. 28,2022/08/23 (2022): #pages#–> 10.3201/eid2810.221126 ; https://wwwnc.cdc.gov/eid/article/28/10/22-1126_article

  8. Clinical characteristics of ambulatory and hospitalised patients with monkeypox virus infection: an observational cohort study ( 1238) Clin Microbiol Infect . Mailhe, M., Beaumont, A. L., Thy, M., Le Pluart, D., Perrineau, S., Houhou-Fidouh, N., Deconinck, L., Bertin, C., Ferré, V. M., Cortier, M., C.,De La Porte Des Vaux,, Phung, B. C., Mollo, B., Cresta, M., Bouscarat, F., Choquet, C., Descamps, D., Ghosn, J., Lescure, F. X., Yazdanpanah, Y., Joly, V., Peiffer-Smadja, N.. 2022/08/27 (2022): #pages#–> 10.1016/j.cmi.2022.08.012 ; #URL#

  9. Natural history of Human Monkeypox in individuals attending a sexual health clinic in Milan, Italy ( 1262) J Infect . Moschese, D., Pozza, G., Giacomelli, A., Mileto, D., Cossu, M. V., Beltrami, M., Rizzo, A., Gismondo, M. R., Rizzardini, G., Antinori, S.. 2022/08/26 (2022): #pages#–> 10.1016/j.jinf.2022.08.019 ; #URL#

  10. Genitourinary Lesions Due to Monkeypox ( 1440) Eur Urol . Gomez-Garberi, M., Sarrio-Sanz, P., Martinez-Cayuelas, L., Delgado-Sanchez, E., Bernabeu-Cabezas, S., Peris-Garcia, J., Sanchez-Caballero, L., Nakdali-Kassab, B., Egea-Sancho, C., Olarte-Barragan, E., Ortiz-Gorraiz, M.. 2022/09/13 (2022): #pages#–> 10.1016/j.eururo.2022.08.034 ; #URL#

  11. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022 ( 1486) MMWR Morb Mortal Wkly Rep . O’Laughlin, K., Tobolowsky, F. A., Elmor, R., Overton, R., O’Connor, S. M., Damon, I. K., Petersen, B. W., Rao, A. K., Chatham-Stephens, K., Yu, P., Yu, Y.. 71,2022/09/16 (2022): 1190–> 10.15585/mmwr.mm7137e1 ; #URL#

  12. Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study ( 1748) Lancet Infect Dis . Angelo, K. M., Smith, T., Camprubí-Ferrer, D., Balerdi-Sarasola, L., Díaz Menéndez, M., Servera-Negre, G., Barkati, S., Duvignaud, A., Huber, K. L. B., Chakravarti, A., Bottieau, E., Greenaway, C., Grobusch, M. P., Mendes Pedro, D., Asgeirsson, H., Popescu, C. P., Martin, C., Licitra, C., de Frey, A., Schwartz, E., Beadsworth, M., Lloveras, S., Larsen, C. S., Guagliardo, S. A. J., Whitehill, F., Huits, R., Hamer, D. H., Kozarsky, P., Libman, M.. 2022/10/11 (2022): #pages#–> 10.1016/s1473-3099(22)00651-x ; #URL#

  13. Estimation of the serial interval of monkeypox during the early outbreak in 2022 ( 1895) J Med Virol . Guo, Z., Zhao, S., Sun, S., He, D., Chong, K. C., Yeoh, E. K.. 2022/10/23 (2022): #pages#–> 10.1002/jmv.28248 ; #URL#

  14. Serial interval and incubation period estimates of monkeypox virus infection in 12 U.S. jurisdictions, May - August 2022 ( 2007) medRxiv . Madewell, Zachary, Charniga, Kelly, Masters, Nina, Asher, Jason, Fahrenwald, Lily, Still, William, Chen, Judy, Kipperman, Naama, Bui, David, Shea, Meghan, Saathoff-Huber, Lori, Johnson, Shannon, Harbi, Khalil, Berns, Abby, Perez, Taidy, Gateley, Emily, Spicknall, Ian, Nakazawa, Yoshinori, Gift, Thomas. #volume# (2022): #pages#–> 10.1101/2022.10.26.22281516 ; http://europepmc.org/abstract/PPR/PPR564657 https://doi.org/10.1101/2022.10.26.22281516

  15. Transmission dynamics of monkeypox in the United Kingdom: contact tracing study ( 2069) Bmj . Ward, T., Christie, R., Paton, R. S., Cumming, F., Overton, C. E.. 379,2022/11/03 (2022): e073153–> 10.1136/bmj-2022-073153 ; #URL#

  16. National Monkeypox Surveillance, Central African Republic, 2001-2021 ( 2104) Emerg Infect Dis . Besombes, C., Mbrenga, F., Schaeffer, L., Malaka, C., Gonofio, E., Landier, J., Vickos, U., Konamna, X., Selekon, B., Dankpea, J. N., Von Platen, C., Houndjahoue, F. G., Ouaïmon, D. S., Hassanin, A., Berthet, N., Manuguerra, J. C., Gessain, A., Fontanet, A., Yandoko, E. N.. 28,2022/11/04 (2022): #pages#–> 10.3201/eid2812.220897 ; https://wwwnc.cdc.gov/eid/article/28/12/22-0897_article

  17. Monkeypox outbreak 2022 – an overview of all cases reported to the Cologne Health Department ( 2181) Research Square . Kröger, Sophia Toya, Lehmann, Max Christian, Treutlein, Melanie, Fiethe, Achim, Kossow, Annelene, Küfer-Weiß, Annika, Nießen, Johannes, Grüne, Barbara. #volume# (2022): #pages#–> 10.21203/rs.3.rs-2251751/v1 ; http://europepmc.org/abstract/PPR/PPR570380 https://doi.org/10.21203/rs.3.rs-2251751/v1

  18. Time scales of human monkeypox transmission in the Netherlands ( 2405) medRxiv . Miura, Fuminari, Backer, Jantien, van Rijckevorsel, Gini, Bavalia, Roisin, Raven, Stijn, Petrignani, Mariska, Ainslie, Kylie E. C., Wallinga, Jacco. #volume# (2022): #pages#–> 10.1101/2022.12.03.22283056 ; http://europepmc.org/abstract/PPR/PPR579534 https://doi.org/10.1101/2022.12.03.22283056

 


7 Archive: 2022-23 acute outbreak phase

With reporting frequencies declining, and with new WHO guidance specifying monthly reporting intervals, it is no longer reliable to present cases by week of report. However, in an effort to retain data availability, we present a record of the acute phase of the 2022-2024 outbreak by reporting week. While the end of the acute phase of the outbreak is not explicitly defined, we present data from 1 January 2022 to 14 April 2023, which corresponds to the week when mpox was no longer considered to be a public health emergency of international concern.

Regional trends are shown below:

7.1 Epidemic curve by date of notification (cases)

Epidemic curve shown by month for cases reported up to 14 April 2023.

7.2 Epidemic curve by date of notification (deaths)

Epidemic curve shown by month for deaths reported up to 14 April 2023.

7.3 Epidemic curve by WHO region (cases)

Epidemic curve shown by month for cases reported up to 14 April 2023. Note different y-axis scales.

 


8 Disclaimers

8.1 Data Overview and Visualizations

The WHO 2022-24 mpox global trends report aims to provide frequently updated data visualizations. Caution must be taken when interpreting all data presented, and differences between information products published by WHO, national public health authorities, and other sources using different inclusion criteria and different data cut-off times are to be expected. While steps are taken to ensure accuracy and reliability, all data are subject to continuous verification and change. All counts are subject to variations in case detection, definitions, laboratory testing, and reporting strategies between countries, states and territories.

Data are compiled and shared with WHO by national public health authorities. Data compilation and submission to WHO Headquarters is done by the WHO Regional Offices and WHO Country Offices.

WHO makes no warranties or representations regarding the contents, appearance, completeness, technical specifications, or accuracy of the report. WHO disclaims all responsibility relating to, and shall not be liable for, any use of the report, the results of such use, or the reliance thereon.

WHO reserves the right to make updates and changes to the report without notice, and accepts no liability for any errors or omissions in this regard.

The user of the report is responsible for the interpretation and use of the analysis and outputs performed by the report. The submission of content to the report does not imply WHO’s approval or endorsement of that content, or that the content is appropriate for any purpose or meets any established standard or requirement

Any designations employed or presentation by the user in its use of the app, including tables and maps, do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries.

All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).

9 Acknowledgements

We gratefully acknowledge the input of national public health staff involved in surveillance activities and data submission to WHO, the WHO regional and country offices for the timely compilation of data, and the European Centre for Disease Prevention and Control (ECDC) for the provision of surveillance data collected via the TESSy platform, as well as external partners who contributed additional insights and contextual information on the data.